BioSpace News Archive

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023.

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial evaluating the safety, tolerability, and antitumor activity of BBT-207 in non-small cell lung cancer (NSCLC) patients with EGFR mutations.

iNtRON Biotechnology has announced that they have signed an “EVALUATION LICENSE AND OPTION AGREEMENT” with Basilea Pharmaceutica Ltd, Allschwil, granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200.